Haimai Medical is a tissue engineering and regenerative medicine technology platform developer. The company focuses on the development and production of allogeneic small-diameter tissue engineered blood vessels, which are suitable for chronic renal failure dialysis vascular access establishment, lower extremity arterial trauma vascular replacement, and lower extremity atherosclerosis. Sclerosis and coronary artery bypass surgery, and develop and produce allogeneic regenerative medicine products (such as tissue-engineered ureters, tissue-engineered heart valves, nerve repair catheters, acellular tissues and organs, etc.) on this technology platform and expand to clinical trials worldwide Research and commercialization to meet growing and far-flung unmet clinical needs. Recently, Haimai Medical completed an angel round of financing of tens of millions of yuan. This round of financing was exclusively funded by Huafang Capital.
This article is reproduced from: https://www.itjuzi.com/investevent/13312331
This site is for inclusion only, and the copyright belongs to the original author.